Low-dose transdermal estradiol for symptomatic perimenopause

Lee P. Shulman*, David Harari

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Objective: To determine whether low-dose transdermal estrogen therapy is associated with a reduction in vasomotor symptoms in women who continue to have menstrual cycles. Design: An open-label, observational evaluation conducted over 12 months in 22 consecutive perimenopausal women with vasomotor symptoms. Results: Improvement in vasomotor symptoms was reported by 16 (73%) of women evaluated. Of responders, 11 characterized symptom relief as complete and 6 as moderate. Fifteen (68%) of the women remained on transdermal estrogen at 12 months. No adverse health-related events were attributed to estrogen therapy. Conclusion: Low-dose transdermal estrogen is well tolerated and was associated with a reduction in complaints of vasomotor symptoms before menopause. The steady-state pharmacokinetics of transdermal delivery of unopposed estrogen may be advantageous in a population sensitive to fluctuations in circulating hormone levels.

Original languageEnglish (US)
Pages (from-to)34-39
Number of pages6
Issue number1
StatePublished - Dec 1 2004


  • Estrogen pharmacokinetics
  • Estrogen therapy
  • Hot flashes
  • Perimenopause
  • Transdermal estrogen
  • Vasomotor symptoms

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Low-dose transdermal estradiol for symptomatic perimenopause'. Together they form a unique fingerprint.

Cite this